/
CRIS
$0.44+$0.12 (+37.69%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$12.5M
39M shares
52-week range
$0.18 – $2.48
11% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
3.49%
Moderate
Price (6 mo)
Loading chart…
Change$-159.56
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.4M | $10.0M | $10.8M | $10.6M | $10.2M | $10.0M | $10.9M | $9.4M |
| Cost of revenue | $563.0K | $503.0K | $534.0K | $533.0K | $257.0K | $212.0K | $98.0K | $45.0K |
| Gross profit | $9.9M | $9.5M | $10.3M | $10.1M | $9.9M | $9.8M | $10.8M | $9.4M |
| Gross margin | 94.6% | 95.0% | 95.1% | 95.0% | 97.5% | 97.9% | 99.1% | 99.5% |
| R&D | $24.4M | $22.3M | $23.1M | $34.9M | $43.3M | $39.5M | $38.6M | $28.3M |
| Operating income | −$29.3M | −$24.4M | −$24.9M | −$42.1M | −$53.0M | −$48.3M | −$44.5M | −$32.9M |
| EBITDA | −$28.5M | −$27.2M | −$24.7M | −$40.8M | −$51.7M | −$45.1M | −$42.6M | −$5.2M |
| Net income | −$32.6M | −$32.1M | −$29.9M | −$45.4M | −$56.7M | −$47.4M | −$43.4M | −$7.6M |
| Net margin | -312.4% | -321.3% | -276.0% | -426.7% | -557.7% | -473.0% | -397.8% | -80.3% |
| EPS (diluted) | -19.67 | -19.37 | -12.29 | -9.92 | -12.14 | -8.96 | -6.88 | -0.58 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-1.58 | $-2.02–$-1.12 | 3 |
| 2027 | $17M | $-1.01 | $-1.37–$-0.66 | 3 |
| 2028 | $29M | $-1.20 | $-3.62–$0.57 | 3 |
| 2029 | $117M | $1.68 | $1.68–$1.68 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Curis Inc
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
www.curis.com- Employees
- 24
- IPO / List date
- Aug 1, 2000
- HQ
- LEXINGTON, MA
Held by traders on TradeandTell
No one on the platform currently holds CRIS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 366,740 | $200.7K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-09-29 | 1-for-20reverse |
| 2018-05-30 | 1-for-5reverse |
Recent trades on TradeandTell
No one on the platform has traded CRIS yet.
